Hormonérzékeny prosztatadaganatok kezelésének új irányai

Translated title of the contribution: New therapeutic options for hormone sensitive prostate cancers

Anikó Maráz, L. Géczi, Zsófia Küronya

Research output: Contribution to journalArticle


During the last decades androgen deprivation therapy (ADT) was the standard treatment of prostate cancers. Survival of metastatic patients is 4 years if they receive ADT, but in case of poor prognosis survival rate is under 3 years. Since 2014 two prospective phase III studies have proven the survival advantage of early docetaxel therapy, administered together with ADT, for metastatic hormone-sensitive prostate cancer patients. Its advantage was even more considerable in case of high-volume metastatic cases. In two other studies the benefit of abiraterone-prednisone therapy combined with ADT was proven in comparison with ADT itself in case of newly diagnosed, metastatic, high-risk, hormone-naïve patients. One prospective study has proven the survival benefit of ADT administered together with radiotherapy of the prostate in case of low volume metastatic diseases. In our analysis we demonstrate these clinical studies and try to answer the contradictory questions about the occasionally overlapping therapeutic options.

Original languageHungarian
Pages (from-to)33-39
Number of pages7
JournalMagyar onkologia
Issue number1
Publication statusPublished - Mar 19 2019


ASJC Scopus subject areas

  • Oncology

Cite this